A Phase 2 interventional study of Etrasimod and Placebo in Eosinophilic Esophagitis, sponsored by Pfizer. Completed at 256 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-06.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 41 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.
Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 20th largest by enrollment of the 111 interventional ones that give a count, is one of 11 that started in 2020, is one of 30 in phase 2, and was the 117th registered.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
Browse Eosinophilic Esophagitis studies →23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Mali
Ages 18–65
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–65
Johns Hopkins University · Sites in United States
Ages 5–21
Kate Farms Inc · Sites in United States
Ages 1–21
Medical College of Wisconsin · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 38 · Phase 3 26 · Phase 4 10
First in 1996; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.
Median enrollment 36 across the 111 interventional studies, 80 across the 53 observational. Of the 112 that completed or were terminated, 55 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 165 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 1 study filed under Eosinophilic Esophagitis — fewer than ten, so there is no comparison to draw.
10 of the studies in Eosinophilic Esophagitis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596252Phase 3Dr. Falk Pharma GmbHOnce Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | 2026-12 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT03312686Indiana UniversityChanges in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study | 2026-12-31 |
| NCT02008903University of Colorado, DenverEsophageal String Test in Eosinophilic Esophagitis | 2027-01 |
| NCT06598462Uniquity One (UNI)A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 165 studies in Eosinophilic Esophagitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for the Extension Treatment Period
Exclusion Criteria:
Discontinue, initiate, or change dosing (dosage/frequency) of the following therapies for EoE within 8 weeks prior to Screening EGD. Participants on any of the following therapy need to stay on a stable regimen during study participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Etrasimod
Drug: Etrasimod
Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period.
Drug: Placebo · Drug: Etrasimod
Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
Also known as: APD334
Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
Also known as: APD334
Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16
Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.
Time frame: Baseline, Week 16
Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16
The DSQ was used to measure the frequency and intensity of dysphagia to solid food. DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score = (Sum of points from questions 2+3 in the daily DSQ)×14 days/(Number of diaries reported with non-missing data). DSQ scores can range from 0 to 84, with a higher score indicating worse dysphagia.
Time frame: Baseline, Week 16
Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16
Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.
Time frame: Baseline, Week 16
Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Time frame: Week 16
Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Time frame: Week 16
Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Maximum Severity During 24 Week Double Blind Treatment Period
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AE is defined as an AE that started or worsened in severity on or after the first dose of study treatment. Severity is classified as Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-Threatening, Grade 5: Death Related to AE.
Time frame: Baseline, up to Week 24
Number of Participants With Serious TEAEs, TEAEs Leading to Study Treatment Discontinuation, TEAEs Leading to Death and TEAEs of Special Interest During 24 Week Double Blind Treatment Period
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 24 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to etrasimod was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
Time frame: Baseline up to Week 24
The study consisted of a Double-Blind treatment period (24 weeks) and an Open Label Extension (OLE) period (28 weeks). Participants who were in the placebo group during the Double-Blind treatment period were re-randomized to etrasimod 1 milligram (mg) or etrasimod 2 mg at entry into the Open Label Extension period.
| Milestone | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose | OLE: Placebo Then Etrasimod 2 mg | OLE: Placebo Then Etrasimod 1 mg |
|---|---|---|---|---|---|
| Started | 41 | 39 | 28 | 0 | 0 |
| Completed | 30 | 31 | 24 | 0 | 0 |
| Not completed | 11 | 8 | 4 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 5 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 1 | 0 | 0 |
| Milestone | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose | OLE: Placebo Then Etrasimod 2 mg | OLE: Placebo Then Etrasimod 1 mg |
|---|---|---|---|---|---|
| Started | 30 | 31 | 0 | 12 | 12 |
| Completed | 21 | 24 | 0 | 11 | 10 |
| Not completed | 9 | 7 | 0 | 1 | 2 |
| Withdrew: Non-compliance | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 1 | 2 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 | 1 | 0 |
Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.
| Percent change | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose |
|---|---|---|---|
| Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 | -58.4 (-86.21 to -26.25) | -39.4 (-71.08 to 78.95) | -21.5 (-57.20 to 55.42) |
The DSQ was used to measure the frequency and intensity of dysphagia to solid food. DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score = (Sum of points from questions 2+3 in the daily DSQ)×14 days/(Number of diaries reported with non-missing data). DSQ scores can range from 0 to 84, with a higher score indicating worse dysphagia.
| Units on a scale | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose |
|---|---|---|---|
| Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16 | -17.11 ± 2.247 | -14.78 ± 2.166 | -19.49 ± 2.602 |
Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.
| eos/hpf | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose |
|---|---|---|---|
| Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 | -46.3 ± 17.46 | -5.7 ± 16.99 | 8.3 ± 22.37 |
| Percentage of participants | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose |
|---|---|---|---|
| Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16 | 22.0 | 12.8 | 0 |
| Percentage of participants | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose |
|---|---|---|---|
| Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16 | 12.2 | 7.7 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AE is defined as an AE that started or worsened in severity on or after the first dose of study treatment. Severity is classified as Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-Threatening, Grade 5: Death Related to AE.
| Participants | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose |
|---|---|---|---|
| TEAE: Grade 1 | 19 | 15 | 8 |
| TEAE: Grade 2 | 9 | 12 | 11 |
| TEAE: Grade 3 | 1 | 0 | 2 |
| TEAE: Grade 4 | 0 | 0 | 0 |
| TEAE: Grade 5 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 24 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to etrasimod was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
| Participants | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose |
|---|---|---|---|
| Serious TEAEs | 0 | 0 | 0 |
| TEAEs leading to study treatment discontinuation | 1 | 0 | 1 |
| TEAEs leading to death | 0 | 0 | 0 |
Collected over Baseline up to a maximum of 61 weeks (35 days screening period, 24 weeks of double-blind treatment period, 28 weeks of active extended treatment, and 4 weeks of follow-up period). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Etrasimod 2 mg | 0/41 (0%) | 0/41 (0%) | 30/41 (73.2%) |
| Experimental: Etrasimod 1 mg | 0/39 (0%) | 0/39 (0%) | 27/39 (69.2%) |
| Placebo Then Etrasimod Any Dose | 0/28 (0%) | 0/28 (0%) | 23/28 (82.1%) |
| OLE: Etrasimod 2 mg | 0/30 (0%) | 0/30 (0%) | 16/30 (53.3%) |
| OLE: Etrasimod 1 mg | 0/31 (0%) | 0/31 (0%) | 19/31 (61.3%) |
| OLE: Placebo Then Etrasimod 2 mg | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| OLE: Placebo Then Etrasimod 1 mg | 0/12 (0%) | 1/12 (8.3%) | 7/12 (58.3%) |
| Event | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose | OLE: Etrasimod 2 mg | OLE: Etrasimod 1 mg | OLE: Placebo Then Etrasimod 2 mg | OLE: Placebo Then Etrasimod 1 mg |
|---|---|---|---|---|---|---|---|
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/41 | 0/39 | 0/28 | 0/30 | 0/31 | 0/12 | 1/12 |
| FallInjury, poisoning and procedural complications | 0/41 | 0/39 | 0/28 | 0/30 | 0/31 | 0/12 | 1/12 |
| Event | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose | OLE: Etrasimod 2 mg | OLE: Etrasimod 1 mg | OLE: Placebo Then Etrasimod 2 mg | OLE: Placebo Then Etrasimod 1 mg |
|---|---|---|---|---|---|---|---|
| Oesophageal food impactionGastrointestinal disorders | 1/41 | 1/39 | 5/28 | 0/30 | 1/31 | 4/12 | 0/12 |
| COVID-19Infections and infestations | 4/41 | 4/39 | 6/28 | 2/30 | 5/31 | 1/12 | 1/12 |
| Hiatus herniaGastrointestinal disorders | 0/41 | 0/39 | 1/28 | 0/30 | 0/31 | 0/12 | 2/12 |
| HeadacheNervous system disorders | 3/41 | 2/39 | 1/28 | 1/30 | 1/31 | 2/12 | 0/12 |
| Alanine aminotransferase increasedInvestigations | 3/41 | 2/39 | 0/28 | 4/30 | 0/31 | 0/12 | 2/12 |
| Aspartate aminotransferase increasedInvestigations | 1/41 | 0/39 | 0/28 | 0/30 | 0/31 | 0/12 | 2/12 |
| NauseaGastrointestinal disorders | 6/41 | 3/39 | 3/28 | 2/30 | 1/31 | 0/12 | 0/12 |
| Eosinophilic oesophagitisGastrointestinal disorders | 0/41 | 1/39 | 3/28 | 1/30 | 0/31 | 0/12 | 0/12 |
| DizzinessNervous system disorders | 4/41 | 4/39 | 1/28 | 0/30 | 1/31 | 1/12 | 0/12 |
| Abdominal painGastrointestinal disorders | 2/41 | 1/39 | 1/28 | 1/30 | 0/31 | 1/12 | 0/12 |
All participants who were randomized to study treatment.
| Age, Continuous(Years) | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose | Total |
|---|---|---|---|---|
| Mean | 35.6 ± 9.80 | 39.9 ± 12.87 | 39.1 ± 11.65 | 38.1 ± 11.52 |
| Sex: Female, Male(Participants) | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose | Total |
|---|---|---|---|---|
| Female | 20 | 17 | 14 | 51 |
| Male | 21 | 22 | 14 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 0 | 9 |
| Not Hispanic or Latino | 36 | 34 | 28 | 98 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Experimental: Etrasimod 2 mg | Experimental: Etrasimod 1 mg | Placebo Then Etrasimod Any Dose | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 2 |
| White | 39 | 38 | 28 | 105 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 256 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2020 to primary completion in Sep 2022, 21 months.
Results were first posted in Oct 2023, 1 year after primary completion.
Of 24 phase 2 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod